Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms

European Journal of Haematology

Volumn 92, Issue 3, 2014, Pages 189-194

  Fu, Yuewen ^a   Schroeder, Thomas ^b   Zabelina, Tatjana ^a   Badbaran, Anita ^a   Bacher, Ulrike ^a,c   Kobbe, Guido ^b   Ayuk, Francis ^a   Wolschke, Christine ^a   Schnittger, Susanne ^c   Kohlmann, Alexander ^c   Haferlach, Torsten ^c   Kröger, Nicolaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

Allogeneic stem cell transplantation; Minimal residual disease; Myelodysplastic myeloproliferative neoplasms; Next generation sequencing; Relapse prevention; Sanger

Indexed keywords

ALLOGENEIC STEM-CELL TRANSPLANTATION; MINIMAL RESIDUAL DISEASE; MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS; NEXT-GENERATION SEQUENCING; RELAPSE PREVENTION; SANGER;

ADULT; AGED; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC-MYELOPROLIFERATIVE DISEASES; PREDICTIVE VALUE OF TESTS; RECURRENCE; STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84894252395     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12223     Document Type: Article

References (33)

1. Vardiman JW, Bennett JM, Bain BJ, Baumann I, Thiele J, Orazi A. Myelodysplastic/myeloproliferative neoplasms, unclassifiable. In: Swerdlow S, Campo E, Harris NL, eds. International Agency for Research on Cancer. WHO Classification of Tumours of Hematopoietic and Lymphoid Tissue. Geneva, Switzerland: World Health Organization; 2008:85-6.
2. Bishop MR, Alyea EP III, Cairo MS, et al. National cancer institute's first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: summary and recommendations from the organizing committee. Biol Blood Marrow Transplant 2011;17:443-54.
3. Symeonidis A, Van BA, Mufti G, et al. Allogeneic stem cell transplantation in patients with chronic myelomonocytic leukaemia: the impact of WHO classification and of the conditioning regimen on the transplantation outcome. Bone Marrow Transplant 2010;45:S241, Abstract P803.
4. Kröger N, Zabelina T, Guardiola P, et al. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the chronic leukaemia working party of the European group for blood and marrow transplantation (EBMT). Br J Haematol 2002;118:67-73.
5. Kerbauy DM, Chyou F, Gooley T, et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocyticleukemia. Biol Blood Marrow Transplant 2005;11:713-20.
6. Ocheni S, Kröger N, Zabelina T, et al. Outcome of allo-SCT for chronic myelomonocyticleukaemia. Bone Marrow Transplant 2009;43:659-61.
7. Krishnamurthy P, Lim ZY, Nagi W, et al. Allogeneic haematopoietic SCT for chronic myelomonocyticleukaemia: a single-centreesperience. Bone Marrow Transplant 2010;45:1502-7.
8. Kröger N, Bacher U, Bader P, et al. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the Committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part I: methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant 2010;16:1187-211.
9. Kröger N, Badbaran A, Holler E, et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2007;109:1316-21.
10. Onida F, Kantarjian HM, Smith TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukaemia: a retrospective analysis of 213 patients. Blood 2002;99:840-9.
11. Kohlmann A, Grossmann V, Klein HU, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukaemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 2010;28:3858-65.
12. Kuo MC, Liang DC, Huang CF, et al. RUNX1 mutations are frequent in chronic myelomonocytic leukaemia and mutations at the C-terminal region might predict acute myeloid leukaemia transformation. Leukaemia 2009;23:1426-31.
13. Tefferi A, Lim KH, Abdel-Wahab O, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN, and AML. Leukaemia 2009;23:1343-5.
14. Gelsi-Boyer V, Trouplin V, Adélaïde J, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009;145:788-800.
15. Schnittger S, Eder C, Jeromin S, et al. ASXL1 und exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with adverses outcome. Leukemia 2013;27:83-91.
16. Bacher U, Haferlach T, Schock C, et al. Implications of NRAS mutations in AML: a study of 2502 patients. Blood 2006;107:3847-53.
17. Kohlmann A, Klein HU, Weissmann S, et al. The Interlaboratory Robustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories. Leukemia 2011;25:1840-8.
18. Grossmann V, Roller A, Klein H-U, et al. Robustness of amplicon deep-sequencing underlines its utility in clinical applications. J Mol Diagn 2013;15:473-84.
19. Porter D, Alyea E, Antin JH, et al. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the Committee on treatment of relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010;16:1467-503.
20. Raanani P, Dazzi F, Sohal J, et al. The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol 1997;99:945-50.
21. Kohlmann A, Nadarajah N, Alpermann T, et al. Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease. Leukemia 2014;28:129-37.
22. Grossmann V, Kohlmann A, Eder C, et al. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance. Leukemia 2011;25:877-873.
23. Abdel-Wahab O, Pardanani A, Patel J, et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 2011;25:1200-2.
24. Bacher U, Haferlach T, Schnittger S, et al. Minimal residual disease diagnostics in myeloid malignancies in the post transplant period. Bone Marrow Transplant 2008;42:145-57.
25. Brüggemann M, Raff T, Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006;107:1116-23.
26. Radich JP, Gehly G, Gooley T, et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995;85:2632-8.
27. Alchalby H, Badbaran A, Zabelina T, et al. Impact of JAK2V617F-mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood 2010;116:3572-81.
28. Alchalby H, Badbaran A, Bacher U, et al. Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT. Bone Marrow Transplant 2010;45:1404-7.
29. Böttcher S, Ritgen M, Pott C, et al. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensusIgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia 2004;18:1637-45.
30. Corradini P, Cavo M, Lokhorst H, et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003;102:1927-9.
31. Kröger N, Badbaran A, Lioznov M, et al. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Exp Hematol 2009;37:791-8.
32. Platzbecker U, Wermke M, Radke J, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2012;26:381-9.
33. Baker M. Digital PCR hits its stride. Nat Methods 2012;9:541-4.